Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...
PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF ...
The announcement comes after a request was made by the Canadian Investment Regulatory Organization (CIRO) to explore the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback